Free Trial

VolitionRx 3/25/2024 Earnings Report

VolitionRx logo
$0.55 +0.02 (+4.17%)
As of 03/28/2025 04:00 PM Eastern

VolitionRx EPS Results

Actual EPS
-$0.11
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

VolitionRx Revenue Results

Actual Revenue
$0.24 million
Expected Revenue
$0.50 million
Beat/Miss
Missed by -$260.00 thousand
YoY Revenue Growth
N/A

VolitionRx Announcement Details

Quarter
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Remove Ads

VolitionRx Earnings Headlines

3VNRX : A Look Ahead: VolitionRX's Earnings Forecast
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
See More VolitionRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like VolitionRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VolitionRx and other key companies, straight to your email.

About VolitionRx

VolitionRx (NYSE:VNRX), a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

View VolitionRx Profile

More Earnings Resources from MarketBeat